朱校
临床药学与药事管理学, 青年研究员

姓      名

 朱校

性      别

 男

职      称

 青年研究员

学      历

 博士

电      话

 

传      真

 

电子邮件

 xiaozhu@fudan.edu.cn

个人主页

 

通讯地址

 上海市张衡路826号

个人简介

复旦大学药学院青年研究员,定量药理学博士。2012年本科毕业于复旦大学药学院,2015年获香港中文大学药学硕士,2019年获奥塔戈大学定量药理学博士,并因博士期间的出色科研成果,获得了国家留学基金管理委员会颁发的2019年度国家优秀自费留学生奖。2019~ 2020年受默多克儿童研究所资助,从事博士后研究。现主要研究方向为群体药代动力学药效学、治疗药物监测、优化试验设计和定量系统药理学。近五年已经发表SCI论文20篇,获得2019年大洋洲定量药理学大会最佳学生口头报告奖和2019年大洋洲临床和实验药理学家和毒理学家学会Fred Fastier奖,并受邀在多个国际学术会议上做口头报告,特别是 2019年在定量药理学两大顶级会议之一的欧洲定量药理学年会(PAGE)的Stuart Beal方法学专题做了大会报告。担任《British Journal of Pharmacology》和《British Journal of Clinical Pharmacology》等多个知名学术期刊的审稿人。此外还积极投身于定量药理学在中国的教育推广,创办有微信公众号“PKPD”,有1500多位订阅者,已发布26篇原创文章,共计超过两万次的阅读量,在国内定量药理界得到了很好的反响。

  

教育背景

2016/03  2019/05 奥塔哥大学,定量药理学博士

2012/08  2015/09香港中文大学,药学硕士

2015/02  2015/07北京大学/辉瑞定量药理学教学中心,交换生

2008/09  2012/07复旦大学,药学理学学士

  

工作经历

2021/07 至今复旦大学药学院青年研究员

2020/03  2021/06默多克儿童研究所Honorary Fellow

2019/11  2020/12奥塔哥定量药理组Postdoctoral Fellow

2019/06  2019/10奥塔哥定量药理组Assistant Research Fellow

2015/10  2016/02葛兰素史克中国上海研发中心临床药理建模仿真部门实习生

  

教学培训

2019/11讲师

培训内容:NONMEM初级课程

地点:Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists - Population Approach Group of Australia & New Zealand (ASCEPT-PAGANZ) 2019 Joint Scientific Meeting, 皇后镇, 新西兰

2017/01讲师

培训内容:Multi-state receptor theory and biased ligands

地点:PAGANZ Meeting 2017, 阿德莱德, 澳大利亚

  

研究方向

定量药理:群体药代动力学和药效学

治疗药物监测

受体理论

优化试验设计

  

所获奖励

2020国家优秀自费留学生奖学金

2019ASCEPT New Zealand Fred Fastier Prize

2019ASCEPT and PAGANZ Student Travel Grants

2019International Society of Pharmacometrics (ISoP) Student Prize for pharmacometrics, PAGANZ Meeting 2019, 奥克兰, 新西兰

2019奥塔哥大学药学院2018年度最佳科研论文

2016 - 2019奥塔哥大学博士奖学金

  

发表论文

1.Brusamarello C, Daley AJ, Zhu X, Landersdorfer C, Gwee A. (2021). How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections? J Antimicrob Chemotherhttps://doi.org/10.1093/jac/dkab065

2.Li ZR, Wang CY, Zhu X, Jiao Z. (2021). Population Pharmacokinetics of Levetiracetam: A Systematic Review. Clin Pharmacokinet 60: 305318.

3.Gwee A, Duffull SB, Zhu X, Tong SY, Cranswick N, McWhinney B, Ungerer J, Francis J, Steer AC. (2020). Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children. PLoS neglected tropical diseases 14(12), e0008886.

4.Zhu X, Finlay DB, Glass M, Duffull SB (2020). Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. Br J Pharmacol https://doi.org/10.1111/bph.15066

5.Ji XW, Xue F, Kang ZS, Zhong W, Hui-san Kuan I, Yang XP, Zhu X, et al. (2020). Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae. Antimicrob Agents Chemother 64(3), pii: e01751-19. (共同通讯)

6.Wang S, Zhu X, Han M, Hao F, Lu W, Zhou T. (2020). Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden. AAPS J 22(2), 45. (共同一作)

7.Kuan IHS, Wright DFB, Duffull SB, Zhu X. (2020). Understanding the association between metformin plasma concentrations and lactate. Br J Clin Pharmacol. doi:10.1111/bcp.14394 (通讯作者)

8.PeñaSilva R, Duffull, SB, Steer AC, JaramilloRincon SX, Gwee A, Zhu X. (2020). Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID19. Br J Clin Pharmacol. doi.org/10.1111/bcp.14476 (通讯作者)

9.Yang L, Yong L, Zhu X, Feng Y, Fu Y, Kong D, Lu W, Zhou TY. (2020). Disease progression model of 4T1 metastatic breast cancer. J Pharmacokinet Pharmacodyn, 47(1), 105-116.

10.Zhu X, Finlay DB, Glass M, Duffull SB (2019). Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. Br J Pharmacol 14:2593-2607 (共同一作)

11.Zhu X, Finlay DB, Glass M, Duffull SB (2019). An intact model for quantifying functional selectivity. Sci. Rep9(1), 2557

12.Liu Z, Galettis P, Broyd SJ, van Hell H, Greenwood LM, de Krey P, Steigler A, Zhu X, et al. (2019). Model-based analysis on systemic availability of coadministered cannabinoids after controlled vaporised administration. Intern Med J doi: 10.1111/imj.14415.

13.Zhu X, Finlay DB, Glass M, Duffull SB (2018). An evaluation of the operational model when applied to quantify functional selectivity. Br J Pharmacol 10: 1654-1668

14.Ji XW, Ji SM, He XR, Zhu X, Chen R, Lu W (2018). Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin 39: 286-293.

15.Deng J, Jhandey A, Zhu X, Yang Z, Yik KFP, Zuo Z, Lam TN (2018). In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. PloS one 13(8), e0203361.

16.Chen YS, Liu ZQ, Chen R, Wang L, Huang L, Zhu X, et al. (2017). Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. Acta Pharmacol Sin 38: 1195-1204.

17.Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH, Shek KY, Zuo Z, Lam TN (2017). A Review of Food-Drug Interactions on Oral Drug Absorption. Drugs 77:1833-1855

18.Hao F, Wang S, Zhu X, Xue J, Li J, Wang L, et al. (2017). Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft. Pharm Res 34: 408-418.

19.Zhu X, Deng J, Zuo Z, Lam TN (2016). An Agent-Based Approach to Dynamically Represent the Pharmacokinetic Properties of Baicalein. AAPS J 18: 1475-1488.

20.Ji XW, Ji SM, Li RT, Wu KH, Zhu X, Lu W, et al. (2016). Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. Acta Pharmacol Sin 37: 825-833.

21.Wang L, Zhu X, Xie C, Ding N, Weng X, Lu W, et al. (2012). Imaging acidosis in tumors using a pH-activated near-infrared fluorescence probe.ChemComm 48: 11677-11679.

22.Chen Y, Zhu X, Yu Y, Cai Y, Li Y, Duan G (2012) Comparison of infrared-assisted extraction and other techniques for analysis of indigo and indirubin in leaves of isatis indigotica fort. J Liq Chromatogr Relat Technol 35: 362-374.

23.季双敏, 朱校, 高柳村,  (2018). 靶介导的药物处置模型研究进展. 中国临床药理学与治疗学, 23(5): 481-487.

24.季双敏, 朱校(2018). 靶点介导的药物处置模型在单克隆抗体药物研发中应用的探讨. 中国临床药理学与治疗学, 23(3): 241-246. (通讯作者)

  

学术报告

1.报告题目:Determination of the pharmacodynamics of vancomycin in young infants via time-to-event analysis。会议名称:PAGANZ Virtual Meeting 2021, 悉尼, 澳大利亚

2.报告题目:An evaluation of timed snapshot signalling bias analyses for nonequilibrium systems。会议名称:ASCEPT-PAGANZ 2019 Joint Scientific Meeting, 皇后镇, 新西兰

3.报告题目:A cohesive model framework of receptor pharmacology: beyond the Emax model。会议名称:Population Approach Group in Europe (PAGE) 2019, 斯德哥尔摩, 瑞典

4.报告题目:Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approachPAGANZ Meeting 2019, 奥克兰, 新西兰

5.报告题目:A kinetic model for describing signalling profiles of the cannabinoid-1 receptor. 会议名称:ASCEPT NZ Meeting 2018, 皇后镇, 新西兰

6.报告题目:Kinetic modelling of ligand mediated internalisation。会议名称:PAGANZ Meeting 2018, 墨尔本, 澳大利亚

7.报告题目:An intact model framework for quantifying functional selectivity。会议名称: ASCEPT NZ Meeting 2017, 皇后镇, 新西兰

8.报告题目:Identifiability analysis of empirical models used for quantifying biased ligands。会议名称:PAGANZ Meeting 2017, 阿德莱德, 澳大利亚

  

专业协会会员

ISoP, PAGANZ, ASCEPT

打印 返回